Search Within

Alexia Elia Iasonos

  1. "Body Imaging Service"
Formats
  1. Journal Article (27)
  2. Meeting Abstract (15)
Groups
  1. Biostatistics Service (42)
  2. Body Imaging Service (42)
  3. Epidemiology and Biostatistics (42)
  4. Radiology, Department of (42)
  5. Department of Medicine (39)
  6. Solid Tumor Oncology Division (37)

More Groups

People
  1. Carol Aghajanian (27)
  2. Qin Zhou (25)
  3. Rachel Grisham (21)
  4. Vicky Makker (18)
  5. Roisin O'Cearbhaill (16)
  6. Jason Konner (15)

More People

Years
  1. 2025 (2)
  2. 2024 (5)
  3. 2023 (5)
  4. 2022 (6)
  5. 2021 (5)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Gynecologic Oncology (10)
  3. Clinical Cancer Research (4)
  4. International Journal of Gynecological Cancer (3)
  5. Cancer (2)
  6. Blood (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. Elsevier Inc. (10)
  3. American Association for Cancer Research (4)
  4. Lippincott Williams & Wilkins (3)
  5. Springer (2)
  6. Wiley Blackwell (2)

More Publishers

Results (42)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: Final results
    Meeting Abstract

    Grisham, R.; Giri, D.; Henson, M.; Iasonos, A.; Zhou, Q.; McDonnell, A.; Girshman, J.; O'Cearbhaill, R.; Zamarin, D.; Aghajanian, C.
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission
    Meeting Abstract

    O'Cearbhaill, R. E.; Gnjatic, S.; Aghajanian, C.; Iasonos, A.; Konner, J. A.; Losada, N.; Sarasohn, D.; Rasalan, T.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
    Journal Article

    Hyman, D. M.; Snyder, A. E.; Carvajal, R. D.; Gerecitano, J. F.; Voss, M. H.; Ho, A. L.; Konner, J.; Winkelmann, J. L.; Stasi, M. A.; Monson, K. R.; more...
    Cancer Chemotherapy and Pharmacology (2015)

    Fulltext@MSK | Save
  • A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer
    Journal Article

    Suidan, R. S.; Ramirez, P. T.; Sarasohn, D. M.; Teitcher, J. B.; Mironov, S.; Iyer, R. B.; Zhou, Q.; Iasonos, A.; Paul, H.; Hosaka, M.; more...
    Gynecologic Oncology (2014)

    Fulltext@MSK | Save
  • Gemcitabine for advanced endometrial cancer: A retrospective study of the Memorial Sloan-Kettering Cancer Center experience
    Journal Article

    Grisham, R. N.; Adaniel, C.; Hyman, D. M.; Ma, W.; Iasonos, A.; Aghajanian, C.; Konner, J.
    International Journal of Gynecological Cancer (2012)

    Fulltext@MSK | Save
  • Gemcitabine for advanced endometrial carcinoma (EMC): A review of the MSKCC experience
    Meeting Abstract

    Grisham, R. N.; Adaniel, C. H.; Hyman, D. M.; Ma, W.; Iasonos, A.; Aghajanian, C.; Konner, J. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma
    Journal Article

    Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C. H.; Noy, A.; Straus, D.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Blood (2009)

    Fulltext@MSK | Save